Reporter February 2024 Archive — Page 1 of 4

Michael R. DeBaun, MD, MPH
February 29, 2024

Michael DeBaun receives Paragon Award from the Doris Duke Charitable Foundation

Vanderbilt’s Michael DeBaun, MD, MS, MPH, has received the Paragon Award for “Innovative Improvements to Clinical Care or Healthcare Delivery” from the Doris Duke Charitable Foundation (DDF).

Group portrait of ten healthcare workers wearing black tops and teal scrub pants, posed in two rows inside a building.
February 29, 2024

Grant helps expand Sexual Assault Nurse Examiner training across Middle Tennessee

Three awardees pose onstage against a red-and-black backdrop; the person on the right holds a framed AAOS recognition plaque with small text.
February 29, 2024

Jed Kuhn and MOON Shoulder Group receive high honor in orthopaedic research

The Multicenter Orthopaedic Outcomes Network (MOON) Shoulder Group received the 2024 Kappa Delta Ann Doner Vaughn Award for advancing treatment methods for patients with atraumatic, symptomatic rotator cuff tears.

Close-up of a lit cigarette with glowing ash and smoke rising against a black background.
February 29, 2024

Study targets nicotine craving in schizophrenia

Vanderbilt’s Heather Burrell Ward, MD, has received a five-year, $928,000 grant from the National Institute on Drug Abuse to test whether an externally applied magnetic field can reduce nicotine craving in people with schizophrenia.

Close-up of black and white keys on a grand piano keyboard.
February 29, 2024

Study finds more pleasant-sounding medical device alarms could reduce annoyance without compromising effectiveness

A new study found that making medical device alarms more musical can significantly reduce perceived annoyance without negatively impacting the ability of research participants to learn and remember the alarms.

Portrait of a smiling man in a dark suit, striped shirt and patterned yellow tie against a brown background.
February 27, 2024

Multi-institutional study of Wilms tumor facilitates enrollment, optimizes treatment

Multi-institutional study finds that enrollment and outcomes were similar across various groups of children participating in therapeutic trials for Wilms tumor — the most common pediatric kidney cancer worldwide.